Technetium-99m-sestamibi scanning in recurrent medullary thyroid carcinoma

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Recurrent medullary thyroid carcinoma (MTC) detection relies on serum calcitonin, but tumor localization is challenging.
• Early detection of recurrent MTC is crucial for effective patient management.

Purpose of the Study:

• To compare the efficacy of 99mTc-sestamibi scans with computed tomographic (CT) scans for localizing recurrent MTC.
• To evaluate the role of 99mTc-sestamibi scintigraphy in patients with elevated calcitonin levels.

Main Methods:

• A comparative study involving 10 patients with recurrent MTC and high serum calcitonin levels.
• 99mTc-sestamibi scans were performed and compared with CT scans; bone scans were also utilized in two patients.

Main Results:

• 99mTc-sestamibi scans identified abnormal uptake in 7/10 patients, particularly those with calcitonin > 6000 ng/L.
• Scans detected more soft tissue lesions in the neck and chest (22 vs 11) compared to CT.
• CT scans were superior for detecting hepatic lesions (47 vs 0), and bone scans for bone lesions (17 vs 6).

Conclusions:

• 99mTc-sestamibi scans are a valuable adjunct to CT and bone scans for localizing recurrent MTC in patients with very high calcitonin.
• 99mTc-sestamibi demonstrates higher sensitivity for soft tissue lesions in the neck and chest.
• CT is preferred for hepatic imaging, and bone scans for osseous metastases; 99mTc-sestamibi is less effective with mildly elevated calcitonin.